2017 American Transplant Congress
The Feared Five Fungal Infections in Kidney Transplant Recipients: 20-Year Experience at a Midwestern Center.
University of Wisconsin, Madison, WI
Invasive fungal infections (IFI) are increasing in kidney transplant recipients (KTR). Here we present our experience with five feared IFIs in KTR transplanted between 01/01/1994…2017 American Transplant Congress
Second-Line Therapy After Standard of Care in Antibody-Mediated Rejection: A Prospective Study.
Paris Translational Research Center for Organ Transplantation, Paris, France
There is a marked heterogeneity in AMR patients' prognosis after SOC treatment including plasma exchange (PE) and intravenous immunoglobulins (IVIG). We investigated whether a composite…2017 American Transplant Congress
Felodipine Diminishes Decline in Glomerular Filtration Rate in Lung Transplanted Patients Treated with Cyclosporine: A Randomized Placebo Controlled Trial.
Background. Calcium channel blockers may ameliorate the decline in renal function caused by calcineurin inhibitors in lung transplant (LTX) recipients. We previously demonstrated a 47…2017 American Transplant Congress
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.
Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…2017 American Transplant Congress
The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…2017 American Transplant Congress
The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.
Medicare coverage for kidney transplant recipients aged <65 years in the US ends 3 years posttransplant, but a significant proportion of recipients remain on Medicare…2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…2017 American Transplant Congress
Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters.
1U of Cinicnnati, Cincinnati; 2Cincinnati Children's, Cincinnati; 3iC42 Clinical Research, Colorado
Tacrolimus (Tac) is a cornerstone immunosuppressant metabolized in the gut and liver, resulting in high intra/inter patient pharmacokinetic (PK) variability. Recipient genotype (RG) impacts tac…2017 American Transplant Congress
Reduced Conversion from IgM Anti-HLA-DSA to IgG Anti-HLA-DSA in Belatacept-Treated vs. Cyclosporine-Treated Patients in BENEFIT and BENEFIT-EXT Trials.
Post-transplant, up to 50% of recipients develop IgM DSA. Half of these patients go on to develop IgG DSA. Importantly, patients that progress to IgG…2017 American Transplant Congress
Mesenchymal Stem Cells Suppress T Cell Proliferation and Improve Allograft Survival in a Nonhuman Primate Transplant Model.
Emory Transplant Center, Emory University, Atlanta, GA
Background: The clinical implementation of costimulation blockade (CoB) provides long-term benefit to transplant recipients, with the short-term drawback of increased acute rejection. Cellular therapies are…
- « Previous Page
- 1
- …
- 97
- 98
- 99
- 100
- 101
- …
- 138
- Next Page »